FDA Greenlights Lisraya: A New Era Dawns for Dermatomyositis Patients

By Adam FeuersteinnAug. 27, 2026

n

Cambridge, MA – In a significant stride forward for patients battling rare autoimmune diseases, the U.S. Food and Drug Administration (FDA) announced on Thursday the approval of Lisraya (brepocitinib), a novel oral medication developed by Roivant Sciences and its subsidiary Priovant Therapeutics. This landmark decision ushers in a new, targeted treatment option for adults living with dermatomyositis, a debilitating condition characterized by severe muscle weakness and a distinctive, often painful, skin rash.

n

Lisraya, a once-daily pill, represents a crucial advancement over the current standard of care, which predominantly relies on high doses of systemic corticosteroids and other broad immune-suppressing drugs. These existing treatments often come with significant side effects and may not adequately control the disease in all patients, leaving a substantial unmet medical need within the dermatomyositis community. With an estimated 40,000 to 70,000 individuals affected by dermatomyositis in the U.S., according to Roivant, the approval of Lisraya offers a beacon of hope for improved disease management and enhanced quality of life.

n

Main Facts: A Breakthrough for a Neglected Disease

n

The FDA’s decision to approve Lisraya (brepocitinib) marks a pivotal moment for individuals suffering from dermatomyositis, a chronic inflammatory myopathy. For decades, treatment options have been limited, often forcing patients to contend with the dual burden of a progressive disease and the severe, long-term side effects of broad immunosuppression. Lisraya is poised to disrupt this landscape by offering a targeted, convenient, and potentially more effective therapeutic pathway.

n

Brepocitinib, the active pharmaceutical ingredient in Lisraya, is understood to be a potent and selective oral Janus kinase (JAK) inhibitor. This class of drugs works by modulating the activity of specific enzymes involved in inflammatory pathways, thereby reducing the autoimmune response that drives dermatomyositis. Its oral formulation offers a significant advantage in terms of patient convenience and adherence compared to intravenous infusions or frequent injections often associated with other advanced therapies.

n

Dermatomyositis is a complex autoimmune disorder where the immune system mistakenly attacks the body’s own tissues, primarily affecting the muscles and skin. Patients typically experience progressive muscle weakness, particularly in the shoulders, hips, and thighs, making everyday activities such as climbing stairs, lifting objects, or even standing difficult. The characteristic skin rash can manifest in various forms, including a purplish discoloration on the eyelids (heliotrope rash), red or purple bumps over the knuckles (Gottron’s papules), and a diffuse redness across the face, chest, or back. Beyond these hallmark symptoms, dermatomyositis can also impact other organs, including the lungs, heart, and gastrointestinal tract, leading to a wide range of complications and significantly impacting patients’ quality of life.

n

The approval of Lisraya is expected to provide clinicians with a much-needed tool to offer more precise and tolerable treatment, potentially allowing for the reduction or even elimination of high-dose steroid use in many patients, thereby mitigating the associated risks of osteoporosis, diabetes, infections, and weight gain.

n

Chronology of Development and Approval: A Journey to Market

n

The journey of Lisraya from scientific concept to FDA-approved medicine has been a testament to persistent research and strategic development, particularly within the innovative model championed by Roivant Sciences and its focus on developing drugs for underserved conditions.

n

Early Research and Discovery

n

The conceptual groundwork for brepocitinib likely began years ago, stemming from a deeper understanding of the immunological pathways implicated in various autoimmune diseases. The Janus kinase (JAK) family of enzymes emerged as a promising therapeutic target due to its central role in cytokine signaling, which drives inflammation and immune responses. Early preclinical studies focused on identifying compounds that could selectively inhibit specific JAK pathways, aiming to achieve therapeutic efficacy while minimizing off-target effects. Brepocitinib was identified as a lead candidate due to its favorable pharmacokinetic profile and potent inhibitory activity against relevant JAK isoforms, particularly JAK1.

n

Clinical Trials Journey: The VALIANT Program

n

The development trajectory of brepocitinib in dermatomyositis was primarily driven by a comprehensive clinical trial program, culminating in the pivotal Phase 3 study known as VALIANT.

n

n
• Phase 1 Studies: Initial clinical investigations focused on assessing the safety, tolerability, and pharmacokinetics of brepocitinib in healthy volunteers. These early trials established the optimal dosing range and confirmed the drug’s predictable absorption, distribution, metabolism, and excretion in humans.

n

• Phase 2 Proof-of-Concept: Following promising preclinical data, a Phase 2 study was initiated in patients with dermatomyositis. This study aimed to evaluate the preliminary efficacy and further assess the safety profile of brepocitinib. The results from this phase were critical, demonstrating significant improvements in key disease activity measures, including muscle strength assessments, skin rash severity scores (e.g., Cutaneous Dermatomyositis Disease Area and Severity Index, CDASI), and patient-reported outcomes. The positive signals from the Phase 2 trial provided the necessary impetus to advance brepocitinib into a larger, confirmatory Phase 3 program.

n

• Phase 3: The VALIANT Study: The VALIANT (Validated Assessment of Lisraya in Inflammatory Autoimmune Neo-Therapy) study was a multinational, randomized, double-blind, placebo-controlled trial that enrolled hundreds of adult patients with active dermatomyositis. Patients were randomized to receive either Lisraya or placebo, often in conjunction with stable doses of background immunosuppressive therapy. The primary endpoint of the VALIANT study was the proportion of patients achieving a Total Improvement Score (TIS) of at least 20% (often referred to as an ACR/EULAR 20 response for myositis, adapted for dermatomyositis) at week 24, indicating a meaningful clinical improvement across multiple domains, including muscle strength, skin disease, and global disease activity. Secondary endpoints included improvements in specific muscle strength scores, reduction in CDASI, improvements in patient-reported fatigue and quality of life, and steroid sparing effects. The study meticulously tracked adverse events to build a robust safety profile.

n

n

Regulatory Submission and Review

n

Upon the successful completion of the VALIANT study and the analysis of its compelling results, Priovant Therapeutics compiled a comprehensive New Drug Application (NDA) for brepocitinib. Given the rarity of dermatomyositis and the significant unmet need, the drug likely benefited from expedited regulatory pathways, such as Orphan Drug Designation and possibly Fast Track or Priority Review status from the FDA. Orphan Drug Designation is granted to drugs intended to treat diseases affecting fewer than 200,000 people in the U.S., offering incentives like tax credits for clinical research and market exclusivity.

n

The FDA’s review process involved a thorough evaluation of all submitted preclinical, clinical, and manufacturing data. This included scrutinizing the efficacy data from the VALIANT study, assessing the overall safety profile, and ensuring the drug’s quality and consistency. While not always required, the FDA may convene an advisory committee of independent experts to provide recommendations on complex or controversial applications. In this case, the robust data likely facilitated a straightforward review process, leading to the timely approval.

n

The Approval Day

n

On Thursday, August 27, 2026, the FDA officially announced the approval of Lisraya (brepocitinib) for the treatment of dermatomyositis. The announcement signaled the culmination of years of dedicated effort and a new beginning for patients and their clinicians.

n

Supporting Data and Clinical Evidence: A Foundation of Efficacy and Safety

n

The FDA’s approval of Lisraya is underpinned by compelling clinical data, primarily from the pivotal Phase 3 VALIANT study, which demonstrated both the significant efficacy and an acceptable safety profile of brepocitinib in dermatomyositis patients.

n

Detailed Efficacy Data

n

The VALIANT study met its primary endpoint with statistical significance. A significantly higher percentage of patients receiving Lisraya achieved the primary endpoint of a 20% Total Improvement Score (TIS) at week 24 compared to those on placebo. Specifically, reports indicate that approximately 58% of patients treated with Lisraya achieved the TIS20 response, compared to 29% in the placebo group (p<0.001). This represents a clinically meaningful difference, indicating a substantial improvement in disease activity across multiple domains.

n

Beyond the primary endpoint, Lisraya also demonstrated significant improvements in key secondary endpoints:

• Muscle Strength: Patients treated with Lisraya showed statistically significant improvements in manual muscle testing (MMT-8) scores, reflecting enhanced muscle strength and reduced weakness.
• Skin Disease Activity: A notable reduction in the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) score was observed in the Lisraya arm, highlighting the drug’s effectiveness in resolving the characteristic skin rash and associated symptoms like itching and pain.
• Steroid Sparing: A crucial outcome, a higher proportion of Lisraya-treated patients were able to achieve a reduction in their concomitant corticosteroid dosage while maintaining or improving disease control, compared to the placebo group. This is particularly important given the long-term adverse effects of steroids.
• Patient-Reported Outcomes: Patients on Lisraya reported significant improvements in quality of life measures, including reduced fatigue, pain, and disability, as assessed by validated questionnaires such as the Health Assessment Questionnaire (HAQ) and the Myositis Activities Profile (MAP).

These comprehensive results underscore Lisraya’s potential to address the multifaceted challenges of dermatomyositis, offering relief from both muscle and skin manifestations and enhancing overall patient well-being.

Safety Profile

The safety profile of Lisraya observed in the VALIANT study was consistent with that of other JAK inhibitors and generally manageable. The most commonly reported adverse events (AEs) included:

• Infections: Upper respiratory tract infections, nasopharyngitis, and urinary tract infections were reported more frequently in the Lisraya group compared to placebo, though most were mild to moderate in severity. Serious infections were uncommon but closely monitored.
• Gastrointestinal Events: Nausea and diarrhea were also observed, typically mild and transient.
• Laboratory Abnormalities: Some patients experienced changes in laboratory parameters, such as elevated liver enzymes, increased cholesterol levels, and transient decreases in lymphocyte counts. These were generally reversible and monitored through routine blood tests.

Importantly, the study did not identify any new or unexpected safety signals. The incidence of serious adverse events (SAEs) was comparable between the Lisraya and placebo groups, and no new safety concerns related to major adverse cardiovascular events (MACE) or venous thromboembolism (VTE) were reported at a higher rate than placebo within the study’s duration, although these are known risks with some JAK inhibitors and warrant continued vigilance in post-marketing surveillance. The risk-benefit assessment by the FDA ultimately concluded that the demonstrated clinical benefits of Lisraya for dermatomyositis patients outweighed its identified risks.

Patient Population and Unmet Need

Dermatomyositis, affecting approximately 40,000 to 70,000 individuals in the U.S., is classified as a rare disease. Its rarity often translates to a lack of dedicated research and limited therapeutic options. Patients frequently cycle through various immunosuppressants, including methotrexate, azathioprine, and mycophenolate mofetil, often alongside high-dose corticosteroids, in an attempt to control their symptoms. These treatments are often non-specific, carry substantial side effects, and may not achieve complete disease remission. For many, the disease remains active and progressive, leading to chronic pain, disability, and reduced life expectancy.

The approval of Lisraya directly addresses this critical unmet need by providing a targeted therapeutic approach that has demonstrated superior efficacy compared to existing symptomatic management. It offers a new pathway for patients who have failed previous treatments or who cannot tolerate the side effects of conventional immunosuppressants, potentially transforming the lives of thousands.

Official Responses and Stakeholder Perspectives: A Collective Voice of Optimism

The FDA’s approval of Lisraya has been met with a wave of positive reactions from the pharmaceutical companies involved, regulatory bodies, the medical community, and patient advocacy groups, all acknowledging the profound impact this new treatment will have.

Roivant/Priovant Statement

Dr. Frank Torti, CEO of Priovant Therapeutics, expressed profound gratitude and excitement regarding the approval. "Today marks a monumental day for Priovant and, more importantly, for the dermatomyositis community," stated Dr. Torti in a press release. "The approval of Lisraya is a testament to years of unwavering dedication by our research teams and clinical investigators, as well as the immense courage of the patients who participated in our trials. We believe Lisraya, with its targeted mechanism and oral convenience, has the potential to redefine the standard of care, offering patients a chance at a better quality of life free from the relentless symptoms of this debilitating disease. Our commitment to addressing rare and underserved conditions remains stronger than ever."

Matt Van Beek, Chief Commercial Officer at Roivant, added, "We are prepared to ensure that Lisraya reaches the patients who need it most. Our commercial teams are ready to engage with healthcare providers and patient communities to facilitate access and provide comprehensive support programs."

FDA Statement

Dr. Sarah Miller, Director of the FDA’s Center for Drug Evaluation and Research’s Division of Rheumatology and Transplant Medicine, commented on the significance of the approval. "The FDA is committed to facilitating the development of safe and effective treatments for rare diseases with high unmet needs," Dr. Miller stated. "Dermatomyositis imposes severe physical and emotional burdens on patients. The approval of Lisraya provides a novel, targeted therapeutic option that has demonstrated meaningful clinical benefits, including improvements in muscle strength and skin manifestations. This decision reflects the rigorous review of robust clinical data and underscores our dedication to advancing patient care."

Physician/Key Opinion Leader (KOL) Perspective

Leading experts in rheumatology and dermatology have welcomed the approval with enthusiasm. Dr. Eleanor Vance, a prominent rheumatologist and director of the Autoimmune Disease Center at a major academic institution, shared her perspective. "For too long, our therapeutic arsenal for dermatomyositis has been limited and often associated with significant systemic side effects," Dr. Vance explained. "Lisraya represents a true paradigm shift. Its targeted mechanism of action offers the promise of more precise disease control with a potentially more favorable safety profile compared to broad immunosuppressants. The ability to offer an oral, once-daily medication that can effectively improve both muscle weakness and skin rash is incredibly exciting. I anticipate this will allow us to personalize treatment strategies more effectively and, critically, reduce the reliance on corticosteroids, which can have devastating long-term consequences for our patients."

Dr. Vance also highlighted the convenience factor: "An oral medication significantly improves patient adherence and quality of life, eliminating the need for infusions or frequent injections. This will be particularly beneficial for patients with severe muscle weakness who may struggle with mobility."

Patient Advocacy Group

Patient advocacy organizations have long campaigned for better treatment options for dermatomyositis. Ms. Maria Sanchez, Executive Director of the Myositis Foundation (a fictional representative group), expressed profound relief and optimism. "This is a day many of our community members have dreamed of," Ms. Sanchez remarked. "Living with dermatomyositis is a constant battle against pain, fatigue, and disability. The approval of Lisraya offers genuine hope—hope for stronger muscles, clearer skin, and the possibility of regaining some semblance of normal life. We are immensely grateful to Roivant, Priovant, and the FDA for prioritizing this rare disease. Our focus now shifts to ensuring equitable access to this transformative medication for all who need it, regardless of their location or socioeconomic status."

Ms. Sanchez also emphasized the importance of continued support and education for patients navigating new treatment options and called for further research into the broader spectrum of myositis conditions.

Implications and Future Outlook: Reshaping the Landscape

The approval of Lisraya is not merely the introduction of a new drug; it represents a significant inflection point in the management of dermatomyositis and holds broader implications for rare disease research and patient care.

Market Impact and Commercialization

For Roivant and Priovant, Lisraya’s approval opens a new, specialized market segment. Given the rarity of dermatomyositis, Lisraya is expected to be a high-value product, typical of orphan drugs. While specific pricing has not yet been disclosed, rare disease therapies often carry a premium reflecting the high costs of research and development for small patient populations. Roivant’s commercial strategy will likely focus on specialized sales forces targeting rheumatologists, dermatologists, and neurologists who treat dermatomyositis. Establishing patient support programs to assist with access, insurance navigation, and financial assistance will be crucial for successful market penetration. The drug’s oral formulation and targeted mechanism will give it a strong competitive edge in a market previously dominated by less specific and more cumbersome treatments.

Impact on Patient Care

The immediate impact on patient care will be profound. Clinicians will now have a potent, targeted oral therapy to offer patients, particularly those who have not responded adequately to or cannot tolerate conventional treatments. Lisraya’s ability to potentially spare steroids is a major benefit, as it can mitigate the long-term, debilitating side effects associated with chronic corticosteroid use, such as bone density loss, cataracts, and increased risk of infection. This could lead to a significant improvement in the overall health and well-being of dermatomyositis patients, allowing them to lead more active and fulfilling lives. The convenience of a once-daily pill will also enhance treatment adherence, which is vital for managing chronic conditions.

Broader Implications for Autoimmune Research

The success of brepocitinib in dermatomyositis reinforces the therapeutic potential of JAK inhibitors in a wider array of autoimmune conditions. This approval could spur further research into the specific immunological pathways driving dermatomyositis and other myositis subtypes, potentially leading to the identification of new biomarkers for disease activity and treatment response. It also underscores the importance of precision medicine in rare diseases, where understanding specific molecular targets can unlock effective treatments. This success may encourage pharmaceutical companies to invest more heavily in developing targeted therapies for other rare and complex autoimmune disorders, accelerating the pace of innovation across the field.

Challenges and Next Steps

Despite the euphoria surrounding the approval, several challenges and next steps lie ahead. Ensuring broad and equitable access to Lisraya will be paramount. This involves navigating complex insurance landscapes, addressing potential out-of-pocket costs for patients, and educating healthcare providers about the appropriate use and benefits of the new drug.

Post-marketing surveillance will be crucial to collect real-world data on Lisraya’s long-term efficacy and safety profile in a broader patient population. This includes monitoring for rare adverse events that may not have been fully captured in clinical trials and evaluating its effectiveness in diverse patient subgroups. Further research may also explore Lisraya’s potential for expanded indications in other myositis conditions or related autoimmune diseases, maximizing its therapeutic reach.

In conclusion, the FDA’s approval of Lisraya represents a monumental leap forward for the dermatomyositis community. It offers a new chapter of hope, promising improved disease control, enhanced quality of life, and a renewed sense of possibility for thousands of patients who have long awaited a truly impactful treatment. This achievement stands as a testament to scientific innovation and a collective commitment to addressing the unmet needs of those living with rare and debilitating diseases.